
## Kristopher K Frese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9747746/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 5153-5164.	7.0	126
2	A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. Nature Cancer, 2020, 1, 437-451.	13.2	103
3	Circulating tumor cells and CDX models as a tool for preclinical drug development. Translational Lung Cancer Research, 2017, 6, 397-408.	2.8	68
4	Will liquid biopsies improve outcomes for patients with small-cell lung cancer?. Lancet Oncology, The, 2018, 19, e470-e481.	10.7	63
5	Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models. Molecular Cancer Research, 2017, 15, 1012-1016.	3.4	49
6	PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways. Scientific Reports, 2017, 7, 15441.	3.3	49
7	The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report. Journal of Thoracic Oncology, 2020, 15, 1836-1843.	1.1	45
8	Targeting DNA damage in SCLC. Lung Cancer, 2017, 114, 12-22.	2.0	36
9	<i>Ex vivo</i> culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. British Journal of Pharmacology, 2019, 176, 436-450.	5.4	34
10	Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. Open Biology, 2021, 11, 200247.	3.6	28
11	Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. Clinical Cancer Research, 2022, 28, 1999-2019.	7.0	20
12	Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. Nature Communications, 2021, 12, 6652.	12.8	14
13	Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin. Npj	3.8	9